Saliva-Based Pregnancy Tests Expand Worldwide
A new partnership brings rapid saliva-based testing to eight international markets for adults seeking pregnancy diagnostics.
Updated on Oct. 28, 2026 in Pregnancy
Live Poll
Would you prefer a saliva-based pregnancy test over traditional urine-based testing for your home use?
VIORA and BioTeke have formed a partnership to manufacture and distribute new saliva-based pregnancy tests globally. The collaboration aims to meet rising consumer demand for non-invasive testing methods.
Why it matters
The development signals a shift toward non-invasive diagnostics in reproductive health, potentially offering a quicker alternative to traditional urine-based pregnancy testing. This partnership intends to scale up international access to this technology across eight markets.
The technology relies on saliva sampling to provide results in 20 seconds, according to the formal agreement between the two firms. While manufacturing capacity is being scaled for international rollout across eight markets, the long-term clinical accuracy relative to current standard urine tests is not fully detailed in the current release.
The players
VIORA
A health technology firm focused on the commercialization and distribution of diagnostic testing solutions.
BioTeke
A manufacturer specializing in the development and production of diagnostic medical devices and healthcare technologies.
The details
The test platform utilizes proprietary technology to detect biomarkers present in saliva samples. By moving away from urine-based collection, the system seeks to simplify the user experience while maintaining diagnostic sensitivity. BioTeke is managing the technical production in their facilities, while VIORA coordinates the supply chain and commercial packaging for retail and wholesale distribution.
Timeline
October 21, 2026: The companies signed the formal partnership expansion agreement.
October 2026: VIORA leadership visited BioTeke manufacturing facilities.
November 16-19, 2026: Both companies will showcase the technology at MEDICA 2026 in Düsseldorf.
Health Landscape
The partnership marks a shift toward rapid, non-invasive home diagnostics in the global reproductive health market. It follows the industry-standard path of using major trade events like the MEDICA exhibition to formalize international distribution agreements for emerging medical devices.
While these tests aim to provide a faster alternative to traditional methods, users should continue to follow manufacturer instructions and confirm initial home results with a healthcare provider. Discussing the accuracy and suitability of new non-invasive testing options with your physician is recommended if you have specific clinical concerns.
The takeaway
The move toward saliva-based pregnancy tests reflects a broader trend in diagnostic technology toward faster, non-invasive options. If you are monitoring for pregnancy, prioritize consistent testing methods and always consult your doctor to discuss results and follow-up care.
What happens next
The companies are scheduled to present their collaboration and technology at the MEDICA 2026 exhibition held in Düsseldorf from November 16 to 19, 2026.
Further reading
For more information on diagnostic tools, visit our guide on Pregnancy.
More information
To learn more about the upcoming launch, Schedule a meeting at MEDICA 2026 directly with the representatives.
Source note: This article includes information reported by Greatreporter -.
Live Poll
Would you prefer a saliva-based pregnancy test over traditional urine-based testing for your home use?
